PACB:NGS-Pacific Biosciences of California Inc.

EQUITY | Medical Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 7.34

Change

+0.06 (+0.82)%

Market Cap

USD 0.74B

Volume

1.35M

Analyst Target

USD 6.42
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Pacific Biosciences of California Inc is engaged in design, development and manufacture of sequencing system to help scientists resolve genetically complex problems.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-01-18 )

Largest Industry Peers for Medical Diagnostics & Research

ETFs Containing PACB

IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.81% 18% F 14% F
Dividend Return N/A N/A N/A N/A F
Total Return -0.81% 18% F 14% F
Trailing 12 Months  
Capital Gain 171.85% 98% N/A 99% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 171.85% 98% N/A 99% N/A
Trailing 5 Years  
Capital Gain 12.92% 44% F 51% F
Dividend Return N/A N/A N/A N/A F
Total Return 12.92% 44% F 46% F
Average Annual (5 Year Horizon)  
Capital Gain 4.86% 53% F 48% F
Dividend Return 4.86% 53% F 44% F
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 57.62% 16% F 15% F
Risk Adjusted Return 8.44% 51% F 34% F
Market Capitalization 0.74B 71% C- 72% C

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -10.05 76% 83%
Price/Book Ratio 12.88 13% 7%
Price / Cash Flow Ratio -3.46 82% 88%
Price/Free Cash Flow Ratio -13.59 82% 84%
Management Effectiveness  
Return on Equity -91.11% 34% 12%
Return on Invested Capital -78.66% 29% 13%
Return on Assets -59.60% 34% 11%
Debt to Equity Ratio 14.50% 73% 73%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.